Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 03.04.2026. Verfasst von Zhaoyang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, MA, United States. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc, Oxford PharmaGenesis Ltd, Oxford, UK, Takeda Pharmaceuticals International AG.
Abstract (Originalsprache)
Introduction
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is a unique and effective treatment for primary immunodeficiency disease (PID), allowing for less frequent administration than conventional subcutaneous immunoglobulin therapies.
Methods
The pharmacokinetics (PK) of fSCIG 10% in pediatric patients (aged 2 to <16 years at screening) with PID was assessed in a prospective, phase 3, open-label, multicenter, clinical trial conducted in the USA. Patients previously treated with intravenous or conventional subcutaneous immunoglobulin therapy (consistent dose for ≥3 months) received fSCIG 10% via a dose ramp-up schedule for ≤6 weeks (Epoch 1), then at full target dose every 3–4 weeks for ≤3 years (Epoch 2). Serum total immunoglobulin G (IgG) trough levels were reported throughout Epoch 2 across pediatric age groups (2 to <6, 6 to <12, and 12 to ≤16 years); serial PK were characterized at the Month 6 infusion. In total, 44 patients (mean age: 9.0 years; 59% male and 91% White) were eligible for the study.
Results
Mean total IgG trough levels during Epoch 2 were similar across age groups. Geometric mean area under the IgG concentration–time curve per week ranged from 63.4 to 76.8 g·day/L, and body weight-adjusted apparent clearance ranged from 1.5 to 1.9 ml/day/kg.
Conclusion
This study showed that serum total IgG trough levels were effectively maintained in pediatric patients with PID treated with fSCIG 10%, regardless of age. The dosing strategy for pediatric patients should be informed by assessing individual IgG levels and clinical status as for adults. Clinical trials registration The study is registered with the ClinicalTrials.gov registry at https://clinicaltrials.gov/ct2/study/NCT03277313 (ClinicalTrials.gov Identifier: NCT03277313).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
- Data Science, Safety & Regulatory, IQVIA, Wayne, PA, United States.
- Global Clinical Sciences, Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
- Clinical Medicine, Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
Förderung
- Takeda Development Center Americas, Inc
- Oxford PharmaGenesis Ltd, Oxford, UK
- Takeda Pharmaceuticals International AG
Zitieren
APA
Li, Z., Teng, Y., Russo-Schwarzbaum, S., & McCoy, B. (2025). Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag003
Vancouver
Li Z, Teng Y, Russo-Schwarzbaum S, McCoy B. Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag003
BibTeX
@article{Li2025,
author = {Li, Zhaoyang and Teng, Yang and Russo-Schwarzbaum, Sharon and McCoy, Barbara},
title = {Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag003}
}
EUVIMED